JPM 2023 Jazz Pharmaceuticals.pdf

1、January 2023141stAnnual J.P.Morgan Healthcare ConferenceInnovating to Transform the Lives of Patients and Their FamiliesJanuary 9,2023GraceEpidiolex patientJanuary 2023Transforming Lives.Redefining Possibilities.2Caution Concerning Forward-Looking StatementsThis presentation contains forward-looking

2、 statements and financial targets,including,but not limited to,statements related to:the Companys growth prospects and future financial and operating results,including Vision 2025 and expectations related thereto;2022 revenue guidance and the Companys expectations related thereto;the Companys abilit

3、y to deliver sustainable growth and enhance value;the Companys commercial expectations,including with respect to revenue diversification,and its expectations for significant growth;the Companys ability to realize the commercial potential of its products,including the blockbuster potential for Epidio

4、lex and its growth opportunities and the ability of Zepzelca to gain market share and its potential approval as a first line therapy;the value and growth potential of its products;the Companys net product sales,goals for net product sales from new and acquired products and net leverage ratio target;

5、the Companys views and expectations relating to its patent portfolio,including with respect to expected patent protection;planned or anticipated clinical trial events,including with respect to initiations,enrollment and data read-outs,and the anticipated timing thereof,including completion of enroll

6、ment in the Zepzelca first line SCLC study and availability of zanidatamabs Phase III top-line GEA data;planned or anticipated regulatory submissions and filings;and other statements that are not historical facts.These forward-looking statements are based on the Companys current plans,objectives,est